Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Down 22.4% in December

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a large decrease in short interest in December. As of December 31st, there was short interest totaling 77,875 shares, a decrease of 22.4% from the December 15th total of 100,401 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 90,581 shares, the days-to-cover ratio is currently 0.9 days. Based on an average daily trading volume, of 90,581 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.6% of the company’s shares are sold short.

Genenta Science Stock Down 5.8%

NASDAQ GNTA traded down $0.08 on Friday, reaching $1.30. The stock had a trading volume of 80,660 shares, compared to its average volume of 72,095. Genenta Science has a 12-month low of $1.28 and a 12-month high of $10.00. The stock has a fifty day moving average price of $1.67 and a two-hundred day moving average price of $2.81.

Genenta Science (NASDAQ:GNTA) last posted its quarterly earnings data on Friday, October 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. Research analysts predict that Genenta Science will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC purchased a new position in shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned 0.07% of Genenta Science at the end of the most recent reporting period. Institutional investors own 15.13% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Genenta Science presently has a consensus rating of “Sell”.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.